deltatrials
Completed OBSERVATIONAL NCT02684838

Vigilant ObservatIon of GlIadeL WAfer ImplaNT Registry (VIGILANT)

Vigilant ObservatIon of GlIadeL WAfer ImplaNT (VIGILANT) Registry: A Multicenter, Observational Registry to Collect Information on the Safety and Effectiveness of Gliadel® Wafer (Carmustine Implant) Used in Usual Medical Practice

Sponsor: Arbor Pharmaceuticals, Inc.

Conditions CNS Tumor
Updated 21 times since 2017 Last updated: Nov 7, 2025 Started: Apr 26, 2016 Primary completion: Jun 23, 2025 Completion: Jun 23, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates CNS Tumor and is currently completed. Arbor Pharmaceuticals, Inc. leads this study, which shows 21 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jul 2017 · 5 months · monthly snapshot~Jul 2017 – ~Aug 2017 · 31 days · monthly snapshot~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshot~Sep 2017 – ~Oct 2017 · 30 days · monthly snapshot~Oct 2017 – ~Apr 2018 · 6 months · monthly snapshot~Apr 2018 – ~May 2018 · 30 days · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Feb 2020 · 20 months · monthly snapshot~Feb 2020 – ~Apr 2020 · 2 months · monthly snapshot~Apr 2020 – ~Nov 2020 · 7 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Mar 2022 · 3 months · monthly snapshot~Mar 2022 – ~Jul 2022 · 4 months · monthly snapshot~Jul 2022 – ~Dec 2023 · 17 months · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Dec 2025 · 3 months · monthly snapshot~Dec 2025 – present · 7 months · monthly snapshot

Change History

21 versions recorded

  1. Dec 2025 — Present [monthly]

    Completed

    Status: Active Not Recruiting → Completed

  2. Sep 2025 — Dec 2025 [monthly]

    Active Not Recruiting

  3. Sep 2024 — Sep 2025 [monthly]

    Active Not Recruiting

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting

  5. Dec 2023 — Jul 2024 [monthly]

    Active Not Recruiting

▶ Show 16 earlier versions

  1. Jul 2022 — Dec 2023 [monthly]

    Active Not Recruiting

    Status: Recruiting → Active Not Recruiting

  2. Mar 2022 — Jul 2022 [monthly]

    Recruiting

  3. Dec 2021 — Mar 2022 [monthly]

    Recruiting

  4. Jan 2021 — Dec 2021 [monthly]

    Recruiting

  5. Nov 2020 — Jan 2021 [monthly]

    Recruiting

  6. Apr 2020 — Nov 2020 [monthly]

    Recruiting

  7. Feb 2020 — Apr 2020 [monthly]

    Recruiting

  8. Jun 2018 — Feb 2020 [monthly]

    Recruiting

  9. May 2018 — Jun 2018 [monthly]

    Recruiting

  10. Apr 2018 — May 2018 [monthly]

    Recruiting

    Phase: NA → None

  11. Oct 2017 — Apr 2018 [monthly]

    Recruiting NA

  12. Sep 2017 — Oct 2017 [monthly]

    Recruiting NA

  13. Aug 2017 — Sep 2017 [monthly]

    Recruiting NA

  14. Jul 2017 — Aug 2017 [monthly]

    Recruiting NA

  15. Feb 2017 — Jul 2017 [monthly]

    Recruiting NA

  16. Jan 2017 — Feb 2017 [monthly]

    Recruiting NA

    First recorded

Apr 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Arbor Pharmaceuticals, Inc.
Data source: Arbor Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Atlanta, United States , Aurora, United States , Baltimore, United States , Bay City, United States , Bridgeton, United States , Buffalo, United States , Columbus, United States , Detroit, United States , Edison, United States and 21 more locations